| Literature DB >> 24588319 |
E Pohler1, M Huber, S E Boonen, M Zamiri, P A Gregersen, M Sommerlund, M Ramsing, D Hohl, W H I McLean, F J D Smith.
Abstract
Entities:
Mesh:
Substances:
Year: 2014 PMID: 24588319 PMCID: PMC4282079 DOI: 10.1111/bjd.12927
Source DB: PubMed Journal: Br J Dermatol ISSN: 0007-0963 Impact factor: 9.302
Fig 1Pedigree, clinical images and mutation analysis of family 1. (a) Pedigree showing a four-generation history of punctate palmoplantar keratoderma. The arrowhead indicates the proband. (b) Punctate hyperkeratotic lesions (arrows) around the lateral edge of the foot and heel on the proband. (c) Palms of the father of the proband showing multiple hyperkeratotic lesions. (d) DNA sequence of codons 86–88 of AAGAB in an unaffected control sample. (e) The same region as in (d) from the proband of family 1. The arrow indicates the heterozygous C>T mutation at c.262 resulting in nonsense mutation p.Gln88*.
Fig 2Pedigrees, clinical images and histology of punctate palmoplantar keratoderma type 1 families 2–5. (a) Pedigrees of the families with the relevant mutations indicated. Arrows denote the proband, and asterisks show individuals in whom AAGAB was sequenced. (b) The palm of the proband of family 3 showing the presence of multiple hyperkeratotic lesions. (c) Haematoxylin and eosin staining of a punch biopsy from palmar skin from the proband in family 3. This shows compact orthokeratosis with a defined central depression within the lesion. (d) The plantar surface of the index case in family 4. Hyperkeratotic lesions coalesce at pressure points. (e) Organization of the protein domains in p34 encoded by AAGAB, illustrating the location of all mutations reported to date. The p.Gln88* mutation highlighted in red is the novel mutation reported in this study.